Motorists risk being hit with an eye-watering £1,000 fine if they fail to declare certain conditions to the DVLA ...

In this Healio Video Perspective from Retina 2025, Allen C. Ho, MD, discusses the growing promise of optogenetic therapy in treating patients with retinal disease.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

She lost her sight when she as only 10 years old. Despite her father’s efforts to seek help from numerous worldwide, she was ...

Yemeni woman travels to UAE for life-changing treatment, reinforcing Abu Dhabi’s status as a global healthcare hub ...

It warns: "You need to tell DVLA about some medical conditions as they can affect your driving. You can be fined up to £1,000 ...

Night blindness, or nyctalopia, is the inability to see well in low light conditions, often signalling an underlying issue ...

THE loss of dark adaptation and night blindness which characterizes the earliest stages of retinitis pigmentosa suggested to us the possibility that one of the fundamental features of the ...

NPI-001 tablets have been granted Fast Track designation by the US FDA for treating retinitis pigmentosa, highlighting their potential to address unmet medical needs. Orphan Drug Designation for ...

A drug that receives Fast Track designation may benefit from more frequent interactions with the FDA throughout drug development. In addition, the Fast Track program allows for Accelerated Approval ...

a clinical-stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other diseases caused by oxidative stress, today announced that the U.S. Food and Drug ...